Objective: To study the association of α2,6-sialic acid (SIA) content in serum IgG anti-dsDNA with human systemic lupus erythematosus disease activity index (SLEDAI) and the effect of sialylated and desialylated (deSIA) IgG anti-dsDNA on lupus B cells.

Methods: Blood from lupus patients was collected to determine the ratio of SIA in isolated IgG anti-dsDNA over serum IgG anti-dsDNA (SIA/IgG anti-dsDNA) ratios, which were plotted against SLEDAI using a receiver-operating-characteristics curve. Lupus B cells were cultured in vitro with chimeric sialylated IgG anti-dsDNA and its deSIA form. Culture supernatants were assayed for anti-inflammatory IL-10 and SIA/IgG anti-dsDNA ratios, which were compared among different pre-treatment groups using t-tests.

Results: The area-under-the-curve (AUC) for anti-dsDNA levels against SLEDAI was 0.791 positively (95% confidence interval [C.I.]: 0.699-0.884) and SIA/IgG anti-dsDNA ratios against SLEDAI yielded an AUC of 0.705 inversely (95% C.I: 0.601-0.809): not significantly different. SIA/IgG anti-dsDNA ratios discriminated significantly between patients without and patients with proteinuria ( = .046). SIA/IgG anti-dsDNA ratios correlated significantly and positively with serum C3c and C4 levels. Pre-treatment with IgG anti-dsDNA and its immune complexes (dsDNA/IgG anti-dsDNA IC) induced higher IL-10 from lupus B cells than medium pre-treatment (most < .01 from day 2 to day 5 culture). DeSIA IgG anti-dsDNA IC induced lower IL-10 ( < .05) and lower SIA/IgG anti-dsDNA ratios ( < .001) from lupus B cells than medium and dsDNA pre-treatment.

Conclusion: α2,6-SIA/IgG anti-dsDNA ratios inversely forecasted SLEDAI scores. Possible mechanisms may be due to the different effects of sialylated and deSIA IgG anti-dsDNA on lupus B cells in terms of IL-10 secretion and SIA/IgG anti-dsDNA ratios.

Download full-text PDF

Source
http://dx.doi.org/10.1177/09612033221099766DOI Listing

Publication Analysis

Top Keywords

anti-dsdna ratios
36
igg anti-dsdna
32
sia/igg anti-dsdna
28
anti-dsdna
19
lupus cells
16
desia igg
12
ratios
9
lupus
8
disease activity
8
igg
8

Similar Publications

Objective: Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to compare the efficacy of rituximab (RTX) followed by belimumab or telitacicept in a real-world cohort.

Methods: A total of 49 refractory lupus nephritis patients were enrolled from four independent centres, subsequently categorised into two treatment groups: belimumab group (n=35) and telitacicept group (n=14) based on their treatment following RTX.

View Article and Find Full Text PDF

The gut mycobiota (fungal microbiota) plays a crucial role in the immune system, potentially impacting autoimmune diseases such as systemic lupus erythematosus (SLE). Despite growing interest, data on intestinal fungi in SLE remain limited. This study thereby investigated the human-mimicked (mice) gut mycobiome and quantitative gut mycobiome analyses using universal fungal internal transcribed spacer 2 (ITS2) DNA next generation sequencing and real-time PCR, tracking time-series dynamics from preclinical to established SLE conditions in two SLE-prone mouse models.

View Article and Find Full Text PDF

Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.

Arthritis Res Ther

November 2024

GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.

Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic, incurable autoimmune disease, prompting the need for effective treatments, such as using extracellular vesicles (EV) from mesenchymal stem cells (iMSCs) primed with immune cell media.
  • In the study, female NZB/W F1 mice were divided into three groups to assess the effects of CM-EV and ASC-EV treatments compared to a control group, with assessment done over 36 weeks.
  • Results showed that CM-EV treatment enhanced survival rates, reduced harmful antibodies, and improved kidney health, while both EV types decreased pro-inflammatory macrophages, indicating their potential in modulating SLE’s immune response.
View Article and Find Full Text PDF

Immune Markers and Inflammatory Cytokines in Granulomatous Lobular Mastitis: A Case-Control Study.

J Inflamm Res

November 2024

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, People's Republic of China.

Purpose: Granulomatous lobular mastitis (GLM) has seen a rising incidence, though its pathogenesis remains unclear, posing challenges for treatment and contributing to high recurrence rates with conventional therapies. While the role of inflammatory and immune factors in GLM has been recognized, a comprehensive clinical evaluation of these markers is still lacking. This study aims to identify potential diagnostic markers and therapeutic targets by comparing immune markers and cytokine levels in GLM patients and healthy controls.

View Article and Find Full Text PDF

Phenotypes of patients with lupus-associated pulmonary hypertension in the Chinese Han population: a cluster analysis.

Clin Rheumatol

December 2024

Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Objective: Pulmonary hypertension (PH) is a severe complication of systemic lupus erythematosus (SLE). This study investigated the clinical features of patients with SLE-PH in China based on disease manifestations and organ involvement to define precise treatment of SLE and early prevention of complications.

Methods: In total, 205 SLE-PH patients were included in this study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!